Loading…
Fractyl Health Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $2.20 | $2.06 | |
| P/S | — | — | 1083.6x |
| P/B | — | 36.9x | 3.5x |
| EPS | -$1.86 | -$1.62 | |
| Profit margin | — | — | -73864.52% |
| ROE | — | -1490.32% | -241.68% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HYPRHyperfine, Inc. | $0.83 | — | 2.4x | — | -96.97% | $88.36M |
| OKYOOKYO Pharma Ltd | $1.67 | — | 7.1x | — | -263.78% | $87.64M |
| ATRAAtara Biotherapeutics, Inc. | $8.81 | — | — | — | — | $88.43M |
| ECORelectroCore, Inc. | $9.63 |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| $86.78M |
| INCRIntercure Ltd. | $5.78 | — | 0.8x | — | -9.27% | $86.72M |
| RLYBRallybio Corp | $16.86 | 2.1x | 0.9x | — | 64.86% | $89.57M |